it maybe semantics, but if the BOD wanted to encourage (or just tease out) superior proposals then why would Dr McColl overtly describe MSD as the best suited partner for CAVATAK ... he should instead be saying MSD are "highly suited"... he's actually saying any other company would be an inferior partner. That's not exactly a warm invitation to other possible bidders is it..?
From the announcement:
“This proposed acquisition culminates years of dedicated work by the Viralytics team and
represents an opportunity for significant value creation for our shareholders. Viralytics is proud to
have progressed its lead investigational candidate CAVATAK to Phase 1 and Phase 2 clinical trials
and, we believe that MSD, the leader in immuno-oncology, is best suited to advance CAVATAK for
the benefit of patients globally, and to realise its potential,” said Dr. Malcolm McColl, managing
director and chief executive officer, Viralytics.
VLA Price at posting:
$1.70 Sentiment: Hold Disclosure: Held
